ClinicalTrials.gg
RecruitingNCT07455292TRANSLATEUpdated Mar 6, 2026

Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging

An interventional study of Cardiac MRI with 4D Flow acquisition and invasive signal routinely collected during transcatheter aortic valve replacement in Left Ventricle Function, Transcatheter Aortic Valve Replacement (TAVR) and Aortic Valve Stenosis, sponsored by IRCCS Policlinico S. Donato. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.

Planned enrollment
29th of 47
190 · median 300
Started
2025
with 9 others
No phase
40 of 118
16 open now
Primary completion
2026-09
later than 30 of 53 live
Registered
112th of 118
by date
Lead sponsor
5 of 118
IRCCS Policlinico S. Donato

Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 29th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2025, is one of 40 with no phase, reaches primary completion later than 30 of the 53 other live ones, and was the 112th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Aortic Valve Stenosis with a site in Italy, or all of them as a file.
02

Study summary

This study aims to enhance and streamline intracardiac 4D Flow magnetic resonance imaging (MRI) processing by increasing automation for the quantitative and systematic assessment of left ventricular (LV) dysfunction. The study is designed to achieve the following three objectives.

The primary objective is to develop a convolutional neural network (CNN)-based deep learning model for the automatic segmentation of the LV endocardial contour throughout the cardiac cycle using intracavitary MRI data. To support model training, a dataset of LV endocardial wall segmentations will be generated from balanced steady-state free precession (bSSFP) images. A purpose-built retrospective MRI database of bSSFP images will be retrieved to accelerate training set creation.

The secondary objective is to develop a numerical framework for non-invasive MRI-based pressure-volume (PV) loop reconstruction and calculation of simplified hemodynamic force descriptors (HDFs). A prospective cohort of patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) will be enrolled. Pre-procedural non-contrast 4D Flow MRI will be acquired, and non-invasive MRI-derived PV loops will be quantitatively compared with invasive catheter-based PV loop measurements. In addition, simplified HDFs will be compared with 4D Flow-derived HDFs to assess their agreement and their potential to elucidate specific features of heart failure-related LV dysfunction.

The tertiary objective is to establish the foundation for a unified, standalone, and clinically deployable framework for comprehensive, automated, and clinician-friendly analysis of LV hemodynamics based on 4D Flow MRI. Internal testing, benchmarking, and structured evaluation by clinical end-users with prior 4D Flow MRI research experience will be conducted to collect feedback and guide further development and clinical translation.

Read the detailed description

The study includes a retrospective and a prospective arm, addressing methodological development, clinical validation, and translational implementation of advanced MRI-based analysis tools.

Within the retrospective arm, a database of short-axis cine balanced steady-state free precession (bSSFP) images of the LV will be retrieved retrospectively and anonymized prior to analysis. The dataset will be divided into a training set (approximately 75% of cases) and a test set (approximately 25%).

For all MRI datasets included in the training set, LV endocardial contours will be delineated throughout the cardiac cycle, employing semi-automatic segmentation tools (Medviso Segment) with manual corrections applied as necessary to ensure accuracy.

The training dataset, together with the corresponding ground-truth LV endocardial segmentations, will be used to train a deep learning convolutional neural network (CNN), e.g., a ResNet architecture, for the automatic delineation of LV endocardial contours from short-axis cine images.

The remaining test set will be used to evaluate the performance of the trained CNN. Automatically generated LV endocardial contours will be compared with the corresponding manual segmentations to benchmark segmentation accuracy and robustness.

As part of the prospective arm of the study, enrolled patients will undergo non-contrast 4D Flow MRI acquisition prior to the scheduled intervention for transcatheter aortic valve replacement (TAVR).

MRI examinations will be acquired on a 1.5 Tesla scanner (MAGNETOM Aera, Siemens Healthcare, Erlangen, Germany). Standard bSSFP cine sequences with retrospective ECG gating will be used to acquire short-axis and long-axis LV views (slice thickness 8 mm, no inter-slice gap, 30 reconstructed cardiac phases). In the same imaging session, 4D Flow MRI data will be acquired using a prototype time-resolved three-dimensional gradient echo sequence with three-directional velocity encoding. A parasagittal-oriented field of view covering the entire LV will be employed. Acquisitions will be performed during free breathing with retrospective ECG triggering and adaptive respiratory gating. Scan parameters will comply with the 2023 update of the 4D Flow Cardiovascular Magnetic Resonance Consensus Statement. No contrast agent will be administered. Non-invasive continuous blood pressure and relevant hemodynamic parameters will be also recorded from the finger arterial pressure waveform using a clinical-grade device (e.g., Finapres® NOVA).

During the TAVR procedure, simultaneous invasive blood pressure measurements will be obtained in the ascending aorta and in the LV using two pigtail catheters, both before and after valve implantation, as required by standard clinical practice during TAVR, thus without impacting on the clinical workflow.

No variations in prophylaxis or follow-up procedures are expected compared with standard clinical practice. Therefore, no additional physical, psychological, or social risks or direct benefits are associated with participation in the study.

Post-processing of 4D Flow MRI data will be performed using a dedicated workflow incorporating in-house software written in Matlab (The MathWorks Inc., Natick, MA, USA), based on prior experience. Processing steps will include correction for eddy currents and velocity aliasing. Intracavitary LV velocity fields will be extracted using both an in-house semi-automatic segmentation tool and the automated deep learning-based LV masking tool developed in the retrospective arm.

Extracted velocity fields will be used to evaluate LV blood flow energetics, including kinetic energy and viscous energy dissipation, flow component subdivision, intraventricular pressure gradients, and intracavitary flow-mediated hemodynamic forces (HDFs). The resulting HDF vectors will be decomposed into basal-apical, septal-lateral, and inferior-anterior components, and their root mean square (RMS) values will be computed over the cardiac cycle.

Non-invasive continuous blood pressure signals derived from finger arterial waveforms will be combined with MRI-derived LV volumes to estimate non-invasive LV pressure-volume (PV) loops using an established methodology. In parallel, invasive LV pressure data acquired during the TAVR procedure via pigtail catheter will be used to generate catheter-based PV loops. Non-invasive MRI-based PV loop parameters will be quantitatively compared with catheter-based measurements using clinically relevant LV indices.

Intracavitary pressure gradients will be computed from the Navier-Stokes equations to derive HDF vectors for each cardiac frame by integrating pressure gradients over the entire LV volume. HDF vectors will be projected onto three orthogonal anatomical directions (basal-apical, septal-lateral, inferior-anterior), and root mean square (RMS) values of each component calculated over the cardiac cycle. Simplified HDFs will be computed using a recently developed method that does not require 4D Flow MRI data and they will be systematically compared with standard 4D Flow MRI-based HDFs on a patient-specific basis. For validation purposes, both simplified and 4D Flow-derived HDFs will also be compared with corresponding measurements obtained using the prototype HDF tool available in the commercial Medis Suite MR software.

Conventional MRI-derived parameters routinely used to assess LV function, including end-diastolic volume, end-systolic volume, and global longitudinal strain, will also be collected.

Demographic variables (e.g., age and sex), relevant clinical characteristics, administered medical therapy, procedural TAVR data, and concomitant medications will be collected and anonymized prior to analysis.

No follow-up visits or assessments are planned as part of this study.

A standalone application for intracardiac 4D Flow MRI analysis will be designed following an incremental build development model. The process will focus on defining the system requirements specification (SyRS), software requirements specification (SRS), and overall software architecture.

A critical evaluation of existing state-of-the-art 4D Flow MRI workflows used in clinical research and of prototype tools available in commercial software (e.g., Medis Suite MR) will be conducted to identify strengths and limitations. Development will proceed through successive stages, with each stage implementing a specific functional component of the overall framework.

The standalone application will build upon existing in-house Matlab-based algorithms but will be implemented in a compiled programming language, allowing execution without requiring pre-installed software on the end-user's system. Development will be supported by a specialized consulting service.

A preliminary version of the standalone application will undergo internal testing, benchmarking, and structured evaluation by a small group of clinical end-users with prior experience in 4D Flow MRI research. Users will independently test the software on predefined use cases. Clinical feedback, criticisms, and suggestions for further development will be collected through structured questionnaires or interviews and used to guide subsequent refinement and clinical translation.

03

Conditions studied

  • Left Ventricle Function
  • Transcatheter Aortic Valve Replacement (TAVR)
  • Aortic Valve Stenosis

Keywords

  • 4D Flow MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age > 18 years old);
  • Diagnosis of severe AS defined according to ESC guidelines with indication to TAVR;
  • Severe aortic stenosis both in normal/high flow status and in low flow status;
  • Signed informed written consent.

Exclusion criteria

Exclusion Criteria:

  • to cardiac MRI due to previous implant with ferromagnetic components;
  • Poor MRI quality impairing image post-processing;
  • Claustrophobia;
  • Unwilling to sign the .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Other
    TRANSLATE Study Population

    The retrospective phase includes adult patients who previously underwent clinically indicated cardiac MRI for left ventricular functional assessment. The prospective phase includes patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, who undergo additional non-contrast 4D Flow MRI and standard invasive hemodynamic measurements as part of routine clinical care. Data from both phases are used for development and validation of automated MRI-based analysis methods.

    Diagnostic Test: Cardiac MRI with 4D Flow acquisition and invasive signal routinely collected during transcatheter aortic valve replacement

Interventions

  • Diagnostic testCardiac MRI with 4D Flow acquisition and invasive signal routinely collected during transcatheter aortic valve replacement

    Cardiac magnetic resonance imaging, including standard cine imaging and non-contrast 4D Flow MRI acquisition. In the prospective phase, invasive and non-invasive hemodynamic signals routinely collected during the transcatheter aortic valve replacement procedure are recorded for research analysis. No additional procedures beyond standard clinical practice are required. This is a low-intervention interventional study in which all imaging acquisitions and hemodynamic measurements are performed according to standard clinical practice, with no modification of diagnostic or therapeutic pathways.

    Also known as: transcatheter aortic valve implantation, 4D Flow MRI, intracardic invasive pressure, non-invasive blood pressure

06

What researchers measure

Primary outcomes

  1. Accuracy of Automatic Left Ventricular Endocardial Segmentation

    Accuracy of a convolutional neural network (CNN)-based model for automatic delineation of the left ventricular (LV) endocardial contour from short-axis cine balanced steady-state free precession (bSSFP) MRI images throughout the cardiac cycle. Automatically generated contours will be compared with expert manual segmentations (ground truth). Segmentation performance will be quantified using the Dice Similarity Index (DICE) and Hausdorff Distance (HD). Inter- and intra-operator variability of manual segmentation and agreement between manual and automatic contours will also be assessed using Bland-Altman analysis.

    Time frame: Completion of the retrospective analysis of cardiac MRI datasets (6 months)

Secondary outcomes

  1. Agreement Between Non-Invasive MRI-Based and Invasive Pressure-Volume Loop Parameters

    Quantitative agreement between non-invasive MRI-derived left ventricular pressure-volume (PV) loop parameters and invasive catheter-based PV loop measurements acquired during the transcatheter aortic valve replacement (TAVR) procedure. Agreement and correlation will be assessed for clinically relevant LV parameters using correlation analysis and limits of agreement.

    Time frame: Up to 1 week after TAVR

  2. Agreement Between Simplified and 4D Flow MRI-Based Hemodynamic Forces

    Level of agreement and correlation between simplified hemodynamic force descriptors (HDFs) and HDFs calculated using standard intracardiac 4D Flow MRI-based analysis (reference standard). Comparisons will be performed for basal-apical, septal-lateral, and inferior-anterior force components using correlation analysis and Bland-Altman methods. Validation will also include comparison with HDF measurements obtained using a commercial prototype software tool.

    Time frame: Up to 1 week after TAVR

  3. Correlation Between Hemodynamic Forces and LV Volumes

    Correlation between LV hemodynamic forces (quantified using 4D Flow MRI and a simplified cine MRI-based method) and LV volumes, namely LV end-diastolic volume (LVEDV, expressed in ml) and LV end-systolic volume (LVESV, expressed in ml). Separate correlations will be calculated for LVEDV and LVESV, respectively.

    Time frame: Up to 1 week after TAVR

  4. Correlation Between Hemodynamic Forces and LV Global Longitudinal and Circumferential Strain

    Correlation between LV hemodynamic forces (quantified using 4D Flow MRI and a simplified cine MRI-based method) and LV endocardial parameters of deformation, namely global longitudinal strain (GLS) and global circumferential strain (GCS). Strain values will be expressed as percentage (%) deformation with separate correlations calculated for GLS and GCS, respectively.

    Time frame: Up to 1 week after TAVR

07

Study locations

2 of 2 sites recruiting
  • IRCCS Policlinico San Donato
    San Donato Milanese, 20097, Italy
    Recruiting
    • Giandomenico Disabato, MD · Contactgiandomenico.disabato@grupposandonato.it · +390252774804
    • Francesco Sturla, PhD · Contactfrancesco.sturla@grupposandonato.it · +390252774353
    • Giandomenico Disabato, MD · Principal investigator
    • Riccardo Gorla, MD, PhD · Sub investigator
    • Francesco Sturla, PhD · Sub investigator
    • Massimo Lombardi, MD · Sub investigator
    • Francesco Bedogni, MD · Sub investigator
    • Sofia Di Filippo, MSc · Sub investigator
  • IRCCS Policlinico San Donato
    San Donato Milanese, 20097, Italy
    Recruiting
    • Francesco Sturla, MD · Contactfrancesco.sturla@grupposandonato.it · +390252774353
    • Riccardo Gorla, PhD · Sub investigator
    • Francesco Bedogni, MD · Sub investigator
    • Massimo Lombardi, MD · Sub investigator
    • Sofia Di Filippo, MSc · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 11 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Mar 6, 2026
StartActual
Oct 13, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07455292
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Oct 13, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Mar 6, 2026

Study contacts

Giandomenico Disabato, MD
Contact
giandomenico.disabato@grupposandonato.it
+390252774804
Francesco Sturla, PhD
Contact
francesco.sturla@grupposandonato.it
+390252774353
Giandomenico Disabato, MD
principal investigator · IRCCS Policlinico S. Donato

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion